Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis

A 15-year follow-up study

R. A. Bermel, B. Weinstock-Guttman, Dennis Bourdette, P. Foulds, X. You, R. A. Rudick

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Disease-modifying drugs are initiated early and continued for years in patients with multiple sclerosis. Long-term tolerability and impact are not known. The objective of this study was to evaluate long-term tolerability of intramuscular interferon beta-1a and effects on disability and quality of life. Patients were evaluated an average of 15 years after randomization into a placebo-controlled, double-blind trial of intramuscular interferon beta-1a for relapsing multiple sclerosis. Patient-reported Expanded Disability Status Scale, the Short Form-36, a visual analog scale of self-care independence, and a living situation questionnaire were administered. Status was ascertained in 79% (136/172) of eligible patients. Analysis focused on 122 living patients. Despite open-label, non-standardized treatment after the 2-year clinical trial, 46% (n= 56) of the patients remained on intramuscular interferon beta-1a. Expanded Disability Status Scale scores were correlated highly with Short Form-36 subcategories and visual analog scale scores. Patients currently using intramuscular interferon beta-1a had a significantly lower mean Expanded Disability Status Scale score (p= 0.011), less progression to Expanded Disability Status Scale milestones, significantly better scores on the physical component of the Short Form-36 (p<0.0001), and reported better general health and greater independence. We conclude that patients continuing to use intramuscular interferon beta-1a had less disability and better quality of life compared with patients not currently using intramuscular interferon beta-1a 15 years after randomization into a clinical trial.

Original languageEnglish (US)
Pages (from-to)588-596
Number of pages9
JournalMultiple Sclerosis
Volume16
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Therapeutics
Random Allocation
Visual Analog Scale
Multiple Sclerosis
Quality of Life
Clinical Trials
Interferon beta-1a
Self Care
Placebos

Keywords

  • Disease-modifying therapy
  • EDSS
  • Interferon beta-1a
  • Long-term
  • Multiple sclerosis
  • Quality of life
  • SF-36

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis : A 15-year follow-up study. / Bermel, R. A.; Weinstock-Guttman, B.; Bourdette, Dennis; Foulds, P.; You, X.; Rudick, R. A.

In: Multiple Sclerosis, Vol. 16, No. 5, 05.2010, p. 588-596.

Research output: Contribution to journalArticle

Bermel, R. A. ; Weinstock-Guttman, B. ; Bourdette, Dennis ; Foulds, P. ; You, X. ; Rudick, R. A. / Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis : A 15-year follow-up study. In: Multiple Sclerosis. 2010 ; Vol. 16, No. 5. pp. 588-596.
@article{0090a14c30f149cba47da65712f7877e,
title = "Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: A 15-year follow-up study",
abstract = "Disease-modifying drugs are initiated early and continued for years in patients with multiple sclerosis. Long-term tolerability and impact are not known. The objective of this study was to evaluate long-term tolerability of intramuscular interferon beta-1a and effects on disability and quality of life. Patients were evaluated an average of 15 years after randomization into a placebo-controlled, double-blind trial of intramuscular interferon beta-1a for relapsing multiple sclerosis. Patient-reported Expanded Disability Status Scale, the Short Form-36, a visual analog scale of self-care independence, and a living situation questionnaire were administered. Status was ascertained in 79{\%} (136/172) of eligible patients. Analysis focused on 122 living patients. Despite open-label, non-standardized treatment after the 2-year clinical trial, 46{\%} (n= 56) of the patients remained on intramuscular interferon beta-1a. Expanded Disability Status Scale scores were correlated highly with Short Form-36 subcategories and visual analog scale scores. Patients currently using intramuscular interferon beta-1a had a significantly lower mean Expanded Disability Status Scale score (p= 0.011), less progression to Expanded Disability Status Scale milestones, significantly better scores on the physical component of the Short Form-36 (p<0.0001), and reported better general health and greater independence. We conclude that patients continuing to use intramuscular interferon beta-1a had less disability and better quality of life compared with patients not currently using intramuscular interferon beta-1a 15 years after randomization into a clinical trial.",
keywords = "Disease-modifying therapy, EDSS, Interferon beta-1a, Long-term, Multiple sclerosis, Quality of life, SF-36",
author = "Bermel, {R. A.} and B. Weinstock-Guttman and Dennis Bourdette and P. Foulds and X. You and Rudick, {R. A.}",
year = "2010",
month = "5",
doi = "10.1177/1352458509360549",
language = "English (US)",
volume = "16",
pages = "588--596",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis

T2 - A 15-year follow-up study

AU - Bermel, R. A.

AU - Weinstock-Guttman, B.

AU - Bourdette, Dennis

AU - Foulds, P.

AU - You, X.

AU - Rudick, R. A.

PY - 2010/5

Y1 - 2010/5

N2 - Disease-modifying drugs are initiated early and continued for years in patients with multiple sclerosis. Long-term tolerability and impact are not known. The objective of this study was to evaluate long-term tolerability of intramuscular interferon beta-1a and effects on disability and quality of life. Patients were evaluated an average of 15 years after randomization into a placebo-controlled, double-blind trial of intramuscular interferon beta-1a for relapsing multiple sclerosis. Patient-reported Expanded Disability Status Scale, the Short Form-36, a visual analog scale of self-care independence, and a living situation questionnaire were administered. Status was ascertained in 79% (136/172) of eligible patients. Analysis focused on 122 living patients. Despite open-label, non-standardized treatment after the 2-year clinical trial, 46% (n= 56) of the patients remained on intramuscular interferon beta-1a. Expanded Disability Status Scale scores were correlated highly with Short Form-36 subcategories and visual analog scale scores. Patients currently using intramuscular interferon beta-1a had a significantly lower mean Expanded Disability Status Scale score (p= 0.011), less progression to Expanded Disability Status Scale milestones, significantly better scores on the physical component of the Short Form-36 (p<0.0001), and reported better general health and greater independence. We conclude that patients continuing to use intramuscular interferon beta-1a had less disability and better quality of life compared with patients not currently using intramuscular interferon beta-1a 15 years after randomization into a clinical trial.

AB - Disease-modifying drugs are initiated early and continued for years in patients with multiple sclerosis. Long-term tolerability and impact are not known. The objective of this study was to evaluate long-term tolerability of intramuscular interferon beta-1a and effects on disability and quality of life. Patients were evaluated an average of 15 years after randomization into a placebo-controlled, double-blind trial of intramuscular interferon beta-1a for relapsing multiple sclerosis. Patient-reported Expanded Disability Status Scale, the Short Form-36, a visual analog scale of self-care independence, and a living situation questionnaire were administered. Status was ascertained in 79% (136/172) of eligible patients. Analysis focused on 122 living patients. Despite open-label, non-standardized treatment after the 2-year clinical trial, 46% (n= 56) of the patients remained on intramuscular interferon beta-1a. Expanded Disability Status Scale scores were correlated highly with Short Form-36 subcategories and visual analog scale scores. Patients currently using intramuscular interferon beta-1a had a significantly lower mean Expanded Disability Status Scale score (p= 0.011), less progression to Expanded Disability Status Scale milestones, significantly better scores on the physical component of the Short Form-36 (p<0.0001), and reported better general health and greater independence. We conclude that patients continuing to use intramuscular interferon beta-1a had less disability and better quality of life compared with patients not currently using intramuscular interferon beta-1a 15 years after randomization into a clinical trial.

KW - Disease-modifying therapy

KW - EDSS

KW - Interferon beta-1a

KW - Long-term

KW - Multiple sclerosis

KW - Quality of life

KW - SF-36

UR - http://www.scopus.com/inward/record.url?scp=77952796371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952796371&partnerID=8YFLogxK

U2 - 10.1177/1352458509360549

DO - 10.1177/1352458509360549

M3 - Article

VL - 16

SP - 588

EP - 596

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 5

ER -